Dr Reddy's Laboratories on June 13 said that it has inked agreement with US-based biopharmaceutical organization <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.bloombergquint.com/business/dr-reddy-s-inks-pact-with-gilead-sciences-for-remdesivir">Gilead Sciences to fabricate and advertise remdesivir - a potential COVID-19 medication in 127 nations, including India.</a></span>
<iframe width="560" height="315" src="https://www.youtube.com/embed/ZJ6Ol-T6f18" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>

According to the non-selective authorizing understanding, Gilead will allow the Hyderabad-based medication creator the option to enroll and fabricate its investigational tranquilize remdesivir in 127 nations, Dr Reddy's Laboratories said in an announcement.

The organization will get innovation move from Gilead for assembling of the medication, it included.

Dr Reddy's would need to scale up assembling and get administrative endorsement for showcasing of this medication in particular nations, the organization said.

Remdesivir, an investigational antiviral treatment created by Gilead, has gotten Emergency Use Authorisation (EUA) by the US Food and Drug Administration (USFDA) to treat COVID-19.